Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 314

1.

C-statistic: A brief explanation of its construction, interpretation and limitations.

Caetano SJ, Sonpavde G, Pond GR.

Eur J Cancer. 2017 Dec 5. pii: S0959-8049(17)31367-9. doi: 10.1016/j.ejca.2017.10.027. [Epub ahead of print] No abstract available.

PMID:
29221899
2.

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL.

J Bone Oncol. 2017 Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001. eCollection 2018 Mar.

3.

Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.

Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O'Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ.

JAMA Otolaryngol Head Neck Surg. 2017 Nov 22. doi: 10.1001/jamaoto.2017.2235. [Epub ahead of print]

PMID:
29167901
4.

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group.

Clin Genitourin Cancer. 2017 Nov 1. pii: S1558-7673(17)30318-X. doi: 10.1016/j.clgc.2017.10.012. [Epub ahead of print]

PMID:
29158079
5.

Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy.

Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL.

J Cancer Surviv. 2017 Oct 27. doi: 10.1007/s11764-017-0656-6. [Epub ahead of print]

PMID:
29080061
6.

Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.

Troncone M, Cargnelli SM, Villani LA, Isfahanian N, Broadfield LA, Zychla L, Wright J, Pond G, Steinberg GR, Tsakiridis T.

Oncotarget. 2017 Apr 27;8(34):57733-57754. doi: 10.18632/oncotarget.17496. eCollection 2017 Aug 22. Review.

7.

Validation of a modified VOICES survey to measure end-of-life care quality: the CaregiverVoice survey.

Seow H, Bainbridge D, Brouwers M, Pond G, Cairney J.

BMC Palliat Care. 2017 Aug 30;16(1):44. doi: 10.1186/s12904-017-0227-7.

8.

Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry.

Goldberg M, Bell K, Aronson M, Semotiuk K, Pond G, Gallinger S, Zbuk K.

J Med Genet. 2017 Nov;54(11):742-746. doi: 10.1136/jmedgenet-2017-104542. Epub 2017 Aug 4.

PMID:
28779004
9.

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.

Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Federico P, Daniele B, Morelli F, Bellelli T, Ferro M, De Placido S, Buonerba C.

Eur Urol Focus. 2017 Apr 8. pii: S2405-4569(17)30083-4. doi: 10.1016/j.euf.2017.03.015. [Epub ahead of print]

PMID:
28753882
10.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Eur Urol Focus. 2017 Mar 31. pii: S2405-4569(17)30079-2. doi: 10.1016/j.euf.2017.03.011. [Epub ahead of print]

PMID:
28753879
11.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

12.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI.

Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10.

PMID:
28579151
13.

Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery.

Greenspoon JN, Ellis PM, Pond G, Caetano S, Broomfield J, Swaminath A.

Curr Oncol. 2017 Apr;24(2):e146-e151. doi: 10.3747/co.24.3420. Epub 2017 Apr 27.

14.

A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer.

Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, Dodd A, Crawley A, Tannock IF.

Brain Imaging Behav. 2017 May 2. doi: 10.1007/s11682-017-9728-5. [Epub ahead of print]

PMID:
28466438
15.

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, Khoo V, Hakenberg OW, Draeger D, Protzel C, Heidenreich A, Haidl F, Eigl BJ, Nappi L, Matsumoto K, Vaishampayan U, Woods ME, Salvioni R, Nicolai N, Catanzaro M, Giannatempo P, Geynisman DM, Preto M, Xylinas E, Milowsky MI, De Placido S, Di Lorenzo G, Sonpavde G.

Clin Genitourin Cancer. 2017 Oct;15(5):548-555.e3. doi: 10.1016/j.clgc.2017.02.002. Epub 2017 Feb 27.

PMID:
28325636
16.

Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer.

Meyers BM, Al-Shamsi HO, Rask S, Yelamanchili R, Phillips CM, Papaioannou A, Pond GR, Jeyabalan N, Zbuk KM, Dhesy-Thind SK.

J Gastrointest Oncol. 2017 Feb;8(1):32-38. doi: 10.21037/jgo.2016.11.12.

17.

A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).

Nguyen NA, Isfahanian N, Pond G, Hanna W, Cutz JC, Wright J, Swaminath A, Shargall Y, Chow T, Wierzbicki M, Okawara G, Quan K, Finley C, Juergens R, Tsakiridis T.

Clin Lung Cancer. 2017 Jul;18(4):436-440.e1. doi: 10.1016/j.cllc.2017.01.007. Epub 2017 Jan 31.

PMID:
28215851
18.

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN.

Lung Cancer. 2017 Feb;104:65-69. doi: 10.1016/j.lungcan.2016.12.004. Epub 2016 Dec 15.

PMID:
28213002
19.

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

Buonerba C, Di Lorenzo G, Pond G, Cartenì G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G.

Front Pharmacol. 2016 Dec 20;7:487. doi: 10.3389/fphar.2016.00487. eCollection 2016.

20.

Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.

Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, Levine M, Whelan T, Bane AL.

PLoS One. 2017 Jan 3;12(1):e0168669. doi: 10.1371/journal.pone.0168669. eCollection 2017.

Supplemental Content

Support Center